In a phase II clinical trial of an altered peptide ligand of myelin basic protein (MBP83-99), instead of inducing regulatory myelin-specific T cells, the peptide had an encephalitogenic effect and led to the exacerbation of MS in a subgroup of patients [75]. This evidence concerns the gene MBP and myeloid sarcoma.